Clinical trial NCT00296296 - References

Diabetes Mellitus, Type 2 — Immunosuppression Impact on the Metabolic Control of Kidney Transplant With Pre-Existing Type 2 Diabetes (DM)

Citation(s)

•   Gerber JC, Stewart DL
  Prevention and control of hypertension and diabetes in an underserved population through community outreach and disease management: a plan of action. J Assoc Acad Minor Phys. 1998;9(3):48-52.
•   Hamar P, Müller V, Kohnle M, Witzke O, Albrecht KH, Philipp T, Heemann U
  Metabolic factors have a major impact on kidney allograft survival. Transplantation. 1997 Oct 27;64(8):1135-9.
•   Maes BD, Kuypers D, Messiaen T, Evenepoel P, Mathieu C, Coosemans W, Pirenne J, Vanrenterghem YF
  Posttransplantation diabetes mellitus in FK-506-treated renal transplant recipients: analysis of incidence and risk factors. Transplantation. 2001 Nov 27;72(10):1655-61.
•   Navasa M, Bustamante J, Marroni C, González E, Andreu H, Esmatjes E, García-Valdecasas JC, Grande L, Cirera I, Rimola A, Rodés J
  Diabetes mellitus after liver transplantation: prevalence and predictive factors. J Hepatol. 1996 Jul;25(1):64-71.
•   Revanur VK, Jardine AG, Kingsmore DB, Jaques BC, Hamilton DH, Jindal RM
  Influence of diabetes mellitus on patient and graft survival in recipients of kidney transplantation. Clin Transplant. 2001 Apr;15(2):89-94.
•   Rigatto C
  Clinical epidemiology of cardiac disease in renal transplant recipients. Semin Dial. 2003 Mar-Apr;16(2):106-10. Review.
•   Sarwal MM, Yorgin PD, Alexander S, Millan MT, Belson A, Belanger N, Granucci L, Major C, Costaglio C, Sanchez J, Orlandi P, Salvatierra O Jr
  Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation. Transplantation. 2001 Jul 15;72(1):13-21.
•   Weir MR, Fink JC
  Risk for posttransplant Diabetes mellitus with current immunosuppressive medications. Am J Kidney Dis. 1999 Jul;34(1):1-13. Review.

Randomized Open Label Study Comparing the Metabolic Control of Kidney Transplant Recipients With Type 2 Diabetes Receiving Either Prograf or Neoral as Part of a ATG Induction, Prednisone Free and Monitored MMF Immunosuppressive Regimen.

Details for clinical trial NCT00296296